Serum Aldo-Keto Reductase Family 1 Member B10 (AKR1B10) as a Potential Biomarker for Diagnosis of Hepatocellular Carcinoma
Ziran Wang,Lingjun Kong,Rui Zhang,Xiaobo Yang,Zhe Cao,Tengda Xu,Han Zhang,Yaling Dou
DOI: https://doi.org/10.2147/jhc.s443006
2024-01-17
Journal of Hepatocellular Carcinoma
Abstract:Ziran Wang, 1, &ast Lingjun Kong, 1, &ast Rui Zhang, 1 Xiaobo Yang, 2 Zhe Cao, 3 Tengda Xu, 4 Han Zhang, 1 Yaling Dou 1 1 Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China; 2 Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China; 3 Hunan Light of Life Biotechnology Co., Ltd., Ningxiang, Hunan, People's Republic of China; 4 Department of Health Management, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China &astThese authors contributed equally to this work Correspondence: Yaling Dou, Department of Clinical Laboratory, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, 100730, People's Republic of China, Email Objective: To evaluate the diagnostic performance of aldo-keto reductase family 1 member B10 (AKR1B10) in a Beijing cohort with hepatocellular carcinoma (HCC). Methods: This study included 521 subjects who visited Peking Union Medical College Hospital from June 2017 to May 2023, including 109 cases of HCC, 165 cases of healthy controls, 106 cases of benign liver diseases, and 141 cases of other cancers. Serum AKR1B10 levels were measured and compared across various groups. Diagnostic performances of serum AKR1B10 and other tumor markers were assessed using receiver operator characteristic (ROC) curves. In addition, a subset of HCC patients who underwent surgical resection were recruited for clinical follow-up study. Results: We found that serum AKR1B10 expression was higher in patients with HCC relative to other control groups. The association between serum AKR1B10 and clinical features of HCC was not observed. Serum AKR1B10 showed a high diagnostic performance for HCC, and when combined with AFP, the diagnostic effectiveness was significantly improved. Specifically, serum AKR1B10 showed superior diagnostic effectiveness for AFP-negative HCC. The clinical follow-up study indicated a gradual decrease in serum AKR1B10 after surgery. Conclusion: Our study demonstrated that serum AKR1B10 is a promising biomarker for HCC, and when used in combination with AFP can significantly improve the detection rate of HCC. Keywords: AKR1B10, AFP, hepatocellular carcinoma, diagnostic performance Hepatocellular carcinoma (HCC) is a common malignant gastrointestinal tumor. In United States, there would be approximately 41,210 new cases of HCC and approximately 29,380 deaths caused by HCC in 2023. 1 The situation seems to be even worse in China. According to a national survey by the National Cancer Center (NCC) of China, there were an estimated 388,800 new cases of HCC in 2016, ranking the fourth highest number of new cases in all cancers, while the estimated number of deaths was 336,400, accounting for the second leading cause of death among all cancers. 2 The pathogenesis of HCC is complex and diverse, involving numerous environmental factors in addition to genetic factors. Risk factors for HCC have been identified for several conditions including hepatitis B and C virus infection, alcohol ingestion, ingestion of the fungal metabolite aflatoxin B1, and non-alcoholic steatohepatitis. 3 Some treatment options (curative treatment, palliative treatments, transplantation, and molecular targeted therapy) are now available based on individual condition. Recently, several studies have indicated that patients may benefit from immunotherapy and immune-based combinations, which has shed light on the treatment and management of HCC. 4–7 Nevertheless, the occurrence of metastases and recurrences as well as the heterogeneity among patients make the prognosis of HCC still unsatisfactory. Patients with HCC in early-stage have the option of surgical resection as the first-line therapy, and the 5-year survival rate can reach at 70%, while patients with HCC in more developed stages have shorter survival periods and only benefit from chemoembolization or sorafenib. 3 Considering the malignancy of HCC, it is critical to accurately identify HCC patients early in their treatment and prognostic management. Serum alpha-fetoprotein (AFP) is a widely-used biomarker for HCC in clinical practice at present, but its diagnostic effectiveness for early-stage HCC is remarkably limited. A meta-analysis indicated that when using AFP to detect early-stage HCC, the sensitivity was 44.4%, the specificity was 84.8% and the area under the curve (AUC) was only 0.52. 8 Besides, Lens -Abstract Truncated-
oncology